This clinical trial is focused on studying the effects of a treatment for Primary Hyperparathyroidism, a condition where the parathyroid glands in the neck produce too much parathyroid hormone, leading to high levels of calcium in the blood. The study will compare the effects of a medication called Zoledronic Acid, which is a type of drug known as a bisphosphonate, with a placebo. Zoledronic Acid is given as a solution through an intravenous infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of the study is to investigate how the treatment affects the bones, kidneys, and cardiovascular system of patients with primary hyperparathyroidism one year after they have undergone surgery to remove the overactive parathyroid glands, a procedure known as parathyroidectomy. Participants in the study will receive either Zoledronic Acid or a placebo before their surgery. The study will monitor changes in bone density, which is a measure of bone strength, as well as other health indicators related to the heart and kidneys over the course of a year following the surgery.

Throughout the study, participants will undergo various assessments to evaluate the effects of the treatment. These assessments will include measurements of bone density at different parts of the body, such as the spine and hip, using techniques like high-resolution peripheral computed tomography (HRpQCT), which is a type of imaging that provides detailed pictures of the bone structure. The study will also look at biochemical markers that indicate bone turnover, which is the process of bone renewal, and will assess the presence of any kidney calcifications or changes in urinary substances. The trial aims to provide valuable insights into the potential benefits of using Zoledronic Acid in managing primary hyperparathyroidism.